MeMed For Profit
The immune system is built to communicate. Our mission is to listen. We apply machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights. MeMed�s machine learning-based diagnostics address key clinical and medical challenges in infectious diseases and inflammatory disorders. MeMed BV Bacterial and viral infections are often clinically indistinguishable
Investors
Connections from
Technology:
Biomarker panels
Number Of Exists:
N/A
Investment Stage:
N/A
Founded Date:
2009
Headquarters:
Tirat Carmel, Hefa, Israel
Employee Number:
101-250
Estimated Revenue:
$26 Million
Investor Type:
N/A
Funding Status:
Late Stage Venture
Industry:
Biomarkers of Longevity